8-KOther Events

REGENERON PHARMACEUTICALS, INC. 8-K Report (May 5, 2003)

Filed May 5, 2003For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. filed a Form 8-K on May 5, 2003, to report its first-quarter 2003 financial results. The filing primarily serves to attach a press release dated May 5, 2003, which contains the detailed financial and operational outcomes for the period. Investors should refer to this press release for specific financial figures, revenue drivers, and any significant developments or outlook provided by the company. This report is crucial for understanding Regeneron's performance at the beginning of 2003. The included press release likely covers key metrics such as revenue, net income, research and development expenses, and any updates on their drug pipeline or clinical trials. Investors are advised to review the content of the press release to assess the company's financial health and strategic direction during this period.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. filed an 8-K report on May 5, 2003.
  • 2The primary purpose of the filing was to report first-quarter 2003 results.
  • 3The report includes a press release dated May 5, 2003, as an exhibit.
  • 4The press release contains detailed information on the company's financial results for Q1 2003.
  • 5Investors are directed to the attached press release for a comprehensive overview of the quarter's performance.
  • 6The filing incorporates the press release by reference into its SEC filings.
  • 7The report is signed by Stuart Kolinski, Vice President & General Counsel.

Frequently Asked Questions

The main purpose of this 8-K filing by Regeneron Pharmaceuticals, Inc. is to report their financial results for the first quarter of 2003. It serves as a formal notification to the SEC and investors about the company's performance during that period.

The detailed financial information for Regeneron's first quarter of 2003 is contained within the press release dated May 5, 2003, which is attached as Exhibit 99(a) to this 8-K filing. The filing directs readers to this press release for the comprehensive results.

While not detailed in the 8-K itself, the attached press release likely covers key financial metrics such as revenue, net income/loss, earnings per share, operating expenses (including research and development), and cash position. It may also include updates on clinical trials, product development, and business outlook.